San Diego-based mostly Viking Therapeutics marked alone as a significant competitor inside the weight loss drug marketplace in February after revealing promising information from the mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection and in March t